Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.87 USD | +3.31% | -1.58% | -6.15% |
Sales 2024 * | 23.95M 1.91B | Sales 2025 * | 72.18M 5.76B | Capitalization | 291M 23.25B |
---|---|---|---|---|---|
Net income 2024 * | -76M -6.06B | Net income 2025 * | -39M -3.11B | EV / Sales 2024 * | 12.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.04 x |
P/E ratio 2024 * |
-4.43
x | P/E ratio 2025 * |
-8.7
x | Employees | 100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.46% |
Latest transcript on Verrica Pharmaceuticals Inc.
1 day | +3.31% | ||
1 week | -1.58% | ||
Current month | +16.05% | ||
1 month | +16.05% | ||
3 months | +18.65% | ||
6 months | +103.86% | ||
Current year | -6.15% |
Managers | Title | Age | Since |
---|---|---|---|
Ted White
CEO | Chief Executive Officer | 59 | 30/11/17 |
Terence Kohler
DFI | Director of Finance/CFO | 46 | 15/07/21 |
Compliance Officer | 60 | 31/08/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Prygocki
BRD | Director/Board Member | 58 | 30/04/18 |
Paul Manning
CHM | Chairman | 68 | 30/11/15 |
Craig Ballaron
BRD | Director/Board Member | 63 | 12/06/19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 6.87 | +3.31% | 111,046 |
25/04/24 | 6.65 | -2.06% | 297,436 |
24/04/24 | 6.79 | -0.88% | 114,880 |
23/04/24 | 6.85 | +0.88% | 86,267 |
22/04/24 | 6.79 | -2.72% | 311,344 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.15% | 291M | |
+25.83% | 661B | |
+26.90% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.09% | 231B | |
+4.84% | 200B | |
-9.41% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- VRCA Stock